We explore synthetic lethal interactions in rare and under-researched cancers using FDA-approved therapies. By targeting oxidative DNA damage, replication-coupled lesions, and checkpoint dysfunction, we aim to rapidly repurpose existing compounds for new clinical indications. This approach shortens the path from discovery to patient application.